September 27, 2024

To all stakeholders,

Perseus Proteomics Inc.
Securities Code: 4882 Growth TSE
ir@ppmx.com

PPMX-T003: Announcement on Registration of Patent Jointly Filed with Juntendo University

Perseus Proteomics Inc. (the Company) is pleased to announce that a patent has been registered in Japan regarding PPMX-T003, an anti-transferrin receptor 1 antibody. This patent was jointly filed with the research group of Chief Professor Norio Komatsu at Faculty of Medicine and Senior Associate Professor Marito Araki at Graduate School of Medicine, Juntendo University (affiliations were at the time of application).

Title of invention:	THERAPEUTIC DRUG FOR POLYCYTHEMIA
Patent No.:	JPB7560815
Registration date:	September 25, 2024

This patent stipulates therapeutic applications of PPMX-T003 for polycythemia vera, among other various applications. The Company and the university have filed applications for patents in other major countries as well. The Company has been striving for strengthening intellectual property rights for a broad range of therapeutic applications of PPMX-T003. Substance patents of this antibody have been already registered and plural applications are under examination.

There is no impact on the financial results for the fiscal year ending March 31, 2025.

END